Modern Approach to Managing Vernal Keratoconjunctivitis

被引:8
作者
Kumar, Sunil [1 ]
Gupta, Nitin [2 ]
Vivian, Anthony J. [3 ]
机构
[1] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada
[2] W Suffok Hosp NHS Trust, Bury St Edmunds IP33 2QZ, Suffolk, England
[3] Addenbrookes Hosp, Cambridge Univ Hosp, Cambridge & Eye Treatment Ctr, Bury St Edmunds, Suffolk, England
关键词
Vernal keratoconjunctivitis; Giant papillae; Mast cells stabilizer; Selective antihistamine; Dual-action drugs; Corticosteroids; Cyclosporine; ALLERGIC CONJUNCTIVITIS; TOPICAL CYCLOSPORINE; LODOXAMIDE; 0.1-PERCENT; MITOMYCIN-C; EFFICACY; EYEDROPS; INJECTION; SAFETY; DEXAMETHASONE; CROMOGLYCATE;
D O I
10.1007/s11882-010-0101-7
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Vernal keratoconjunctivitis (VKC), an allergic inflammation of the conjunctiva affecting mainly children and adolescents, is categorized under the rubric of allergic conjunctivitis. Lack of uniform diagnostic and predefined staging criteria has been a bottleneck in formulating fixed guidelines to treat VKC. This lack of consensus among clinicians/researchers regarding diagnostic and grading standards has prevented us from making comparisons between the outcomes of different studies. To treat VKC, selection of a drug from many available options should be based on the duration and frequency of symptoms, grade and inflammation of giant papillae, and severity of corneal involvement. Consideration also should be given to the patient's specific needs. The basic tenet of treatment is optimal control of symptoms with a minimum of toxic side effects resulting from prolonged use of medication.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 50 条
  • [31] Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives
    Chigbu, DeGaulle, I
    Labib, Bisant A.
    PHARMACEUTICALS, 2021, 14 (07)
  • [32] Ocular surface disease: A case of vernal keratoconjunctivitis
    Chigbu, DeGaulle I.
    Sandrasekaramudaly-Brown, Shanthy
    CONTACT LENS & ANTERIOR EYE, 2011, 34 (01) : 39 - 44
  • [33] Corneal complications of vernal keratoconjunctivitis
    Solomon, Abraham
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 15 (05) : 489 - 494
  • [34] Therapeutic options in vernal keratoconjunctivitis
    Messmer, E. M.
    OPHTHALMOLOGE, 2009, 106 (06): : 557 - 561
  • [35] Vernal keratoconjunctivitis (KCV) in the horse
    Toth, Jozsef
    Buijs, Lieke
    PFERDEHEILKUNDE, 2021, 37 (03): : 258 - 266
  • [36] A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis
    Leonardi, Andrea
    Doan, Serge
    Amrane, Mourad
    Ismail, Dahlia
    Montero, Jesus
    Nemeth, Janos
    Aragona, Pasquale
    Bremond-Gignac, Dominique
    OPHTHALMOLOGY, 2019, 126 (05) : 671 - 681
  • [37] Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis
    Coban-Karatas, Muge
    Ozkale, Yasemin
    Altan-Yaycioglu, Rana
    Sizmaz, Selcuk
    Pelit, Aysel
    Metindogan, Sevda
    Canturk-Ugurbas, Silay
    Aydin-Akova, Yonca
    TURKISH JOURNAL OF PEDIATRICS, 2014, 56 (04) : 410 - 417
  • [38] Stability and Safety Traits of Novel Cyclosporine A and Tacrolimus Ophthalmic Galenic Formulations Involved in Vernal Keratoconjunctivitis Treatment by a High-Resolution Mass Spectrometry Approach
    Ghiglioni, Daniele Giovanni
    Martino, Piera Anna
    Bruschi, Gaia
    Vitali, Davide
    Osnaghi, Silvia
    Corti, Maria Grazia
    Beretta, Giangiacomo
    PHARMACEUTICS, 2020, 12 (04)
  • [39] Applications of topical immunomodulators enhance clinical signs of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC): a meta-analysis
    Erdinest, Nir
    Noyman, Dror Ben Ephraim
    London, Naomi
    Lavy, Itay
    Levinger, Nadav
    Landau, David
    Solomon, Abraham
    Morad, Yair
    Naroo, Shehzad A.
    INTERNATIONAL OPHTHALMOLOGY, 2024, 44 (01)
  • [40] Efficacy of a Cationic Emulsion of Cyclosporine in Moderate Vernal Keratoconjunctivitis
    Caputo, Roberto
    Di Grande, Laura
    de Libero, Cinzia
    Marziali, Elisa
    Mori, Francesca
    Masini, Marzio
    CORNEA, 2024, 43 (02) : 228 - 232